Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors

Company Performance - Zoetis (ZTS) closed at $163.03, with a slight decrease of -0.08% from the previous trading session, underperforming the S&P 500 which gained 0.08% [1] - Over the last month, Zoetis shares increased by 3.65%, outperforming the Medical sector's decline of 1.03% and the S&P 500's loss of 7.33% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with expected EPS of$ 1.41, reflecting a 2.17% increase from the prior-year quarter [2] - Quarterly revenue is projected at $2.19 billion, up 0.12% from the year-ago period [2] Full Year Estimates - For the full year, analysts expect earnings of$ 6.12 per share and revenue of $9.31 billion, indicating changes of +3.38% and +0.59% respectively from last year [3] Analyst Estimates - Recent changes in analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating confidence in the company's performance [4] Zacks Rank and Valuation - Zoetis currently holds a Zacks Rank of 4 (Sell), with a Forward P/E ratio of 26.68, which is a premium compared to the industry's average Forward P/E of 17.23 [6] - The Zacks Consensus EPS estimate has shifted 0.14% upward over the past month [6] PEG Ratio - The company has a PEG ratio of 2.86, compared to the Medical - Drugs industry's average PEG ratio of 0.99 [7] Industry Ranking - The Medical - Drugs industry, part of the Medical sector, has a Zacks Industry Rank of 82, placing it in the top 33% of over 250 industries [8]